Literature DB >> 30454973

MiR-196b affects the progression and prognosis of human LSCC through targeting PCDH-17.

Min Luo1, Gang Sun2, Jing-Wu Sun3.   

Abstract

OBJECTIVE: To explore the effect of miR-196bon the biological features of human laryngeal squamous cell carcinoma (LSCC) through targeting PCDH-17.
METHODS: miR-196b and PCDH-17 expressions were determined in tissues, and the targeting relation of miR-196b and PCDH-17 was verified through dual-luciferase reporter system. In vitro, Hep-2 cells were divided into the Control, miR-196b inhibitors, miR-NC, PCDH-17, and miR-196b mimics+PCDH-17 groups. The miR-196b and PCDH-17 expressions were determined by qRT-PCR or/and Western blot, and the biological features by MTT, Annexin V-FITC/PI, wound-healing and Transwell assays.
RESULTS: MiR-196b was found to be up-regulated, while PCDH-17 was down-regulated in a negative correlation in LSCC patients, which was related to histological grade and TNM stage. And low expression of miR-196b and high expression of PCDH-17 contributed to an increase in the 5-year-survival rate of LSCC patients. Besides, miR-196b directly targeted PCDH-17, while miR-196b inhibitors could up-regulate the PCDH-17 in Hep-2 cells. Moreover, miR-196b inhibitors and PCDH-17 curbed Hep-2 cell proliferation but facilitated the apoptosis, with decreases in cell invasion and migration. In addition, no statistical significance was found in cell proliferation, apoptosis, invasion and migration between Control group and miR-196b mimics+PCDH-17 group.
CONCLUSION: LSCC patients exhibited the up-regulated miR-196b and down-regulated PCDH-17, which are correlated with the major clinical features and prognosis. Inhibiting miR-196b may suppress proliferation, migration and invasion abilities, and promote apoptosis of Hep-2 cells via targeting PCDH-17.
Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  LSCC; PCDH-17; Prognosis; miR-196b

Mesh:

Substances:

Year:  2018        PMID: 30454973     DOI: 10.1016/j.anl.2018.10.020

Source DB:  PubMed          Journal:  Auris Nasus Larynx        ISSN: 0385-8146            Impact factor:   1.863


  6 in total

Review 1.  Potential Role of miR-196a and miR-196b as Prognostic Biomarkers of Survival in Head and Neck Squamous Cell Carcinoma: A Systematic Review, Meta-Analysis and Trial Sequential Analysis.

Authors:  Mario Dioguardi; Stefania Cantore; Diego Sovereto; Lucia La Femina; Giorgia Apollonia Caloro; Francesca Spirito; Salvatore Scacco; Michele Di Cosola; Lorenzo Lo Muzio; Giuseppe Troiano; Andrea Ballini
Journal:  Life (Basel)       Date:  2022-08-19

2.  LncRNA NCK1-AS1 Promotes Malignant Cellular Phenotypes of Laryngeal Squamous Cell Carcinoma via miR-137/NCK1 Axis.

Authors:  Lanlan Wan; Dongsheng Gu; Xin Jin
Journal:  Mol Biotechnol       Date:  2022-02-26       Impact factor: 2.860

3.  Hypermethylation-Mediated Silencing of CIDEA, MAL and PCDH17 Tumour Suppressor Genes in Canine DLBCL: From Multi-Omics Analyses to Mechanistic Studies.

Authors:  Eleonora Zorzan; Ramy Elgendy; Giorgia Guerra; Silvia Da Ros; Maria Elena Gelain; Federico Bonsembiante; Giulia Garaffo; Nicoletta Vitale; Roberto Piva; Laura Marconato; Luca Aresu; Mauro Dacasto; Mery Giantin
Journal:  Int J Mol Sci       Date:  2022-04-05       Impact factor: 5.923

Review 4.  Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs.

Authors:  Arsinoe C Thomaidou; Panagiota Batsaki; Maria Adamaki; Maria Goulielmaki; Constantin N Baxevanis; Vassilis Zoumpourlis; Sotirios P Fortis
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

Review 5.  Mesenchymal stem cell-derived exosomes as new tools for delivery of miRNAs in the treatment of cancer.

Authors:  Aysegul Dalmizrak; Ozlem Dalmizrak
Journal:  Front Bioeng Biotechnol       Date:  2022-09-26

6.  A Comprehensive Evaluation of miR-144-3p Expression and Its Targets in Laryngeal Squamous Cell Carcinoma.

Authors:  Bin-Yu Mo; Jin-Shu Pang; Wen-Bin Dai; Ya-Si Su; Wei Jiang; Su-Ning Huang
Journal:  Comput Math Methods Med       Date:  2021-07-16       Impact factor: 2.238

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.